Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study

Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study

ABSTRACT Introduction: the use of palivizumab as prophylaxis of the respiratory syncytial virus is not a consensus. In Brazil, it is a public health program, but other countries do not consider it cost-effective. Objective: to identify the rate of hospitalization in Intensive Care Unit for respira...

Full description

Bibliographic Details
Main Authors:	Ivana Regina Gonçalves, Marli Teresinha Cassamassimo Duarte, Helio Rubens de Carvalho Nunes, Rubia de Aguiar Alencar, Cristina Maria Garcia de Lima Parada
Format:	Article
Language:	English
Published:	Universidade de São Paulo 2017-09-01
Series:	Revista Latino-Americana de Enfermagem
Subjects:	Health Policy Palivizumab Risk Groups Newborn Passive Immunization
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-11692017000100371&lng=en&tlng=en

Similar Items

Avaliação do programa de uso da imunoglobulina palivizumabe no Estado de São Paulo, Brasil
by: Ivana Regina Gonçalves, et al.
Published: (2018-07-01)

Avaliação do programa de uso da imunoglobulina palivizumabe no Estado de São Paulo
by: Gonçalves, Ivana Regina
Published: (2016)

Avaliação do programa de uso da imunoglobulina palivizumabe no Estado de São Paulo
by: Gonçalves, Ivana Regina [UNESP]
Published: (2016)

PROFILAXIA CU PALIVIZUMAB LA SUGARII CU MALFORMAŢII CARDIACE CONGENITALE
by: Amalia Făgărăşan, et al.
Published: (2013-06-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)

Palivizumab nella profilassi del virus respiratorio sinciziale: analisi di impatto sul budget del SSN italiano
by: Daniela Roggeri
Published: (2011-07-01)

Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016-02-01)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
by: Antonino Capizzi, et al.
Published: (2017-08-01)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
by: Abushahin A, et al.
Published: (2018-01-01)

The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants
by: Bykova Е.М., et al.
Published: (2016-06-01)

Cost effectiveness of a protocol using palivizumab in preterm infants
by: Yolanda Hernández-Gago, et al.
Published: (2017-03-01)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study
by: Anushi E. Rajapaksa, et al.
Published: (2020-08-01)

Decreased Hospitalizations for RSV Infection in Children with Congenital Heart Disease: Analysis of a Nationally Representative Sample in the Palivizumab Era
by: Leahy, Ryan
Published: (2011)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
by: Silva Camila de A, et al.
Published: (2012-05-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01)

Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective
by: Eva Fernlund, et al.
Published: (2020-10-01)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
by: Saleh al-Alaiyan, et al.
Published: (2015-02-01)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
by: M. Sanchez-Luna, et al.
Published: (2017-10-01)

Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease
by: Karel Allegaert, et al.
Published: (2015-01-01)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)

Avaliação da susceptibilidade de mutantes de escape do vírus sincicial respiratório frente ao Palivizumab pelo método de microneutralização in vitro.
by: Melo, Stella Rezende
Published: (2017)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
by: Rodica Gilca, et al.
Published: (2020-12-01)

Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection
by: Masaaki Mori, et al.
Published: (2021-03-01)

Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
by: Ralph Schmidt, et al.
Published: (2017-12-01)

Immunoprophylaxis of respiratory syncytial virus: global experience
by: Simoes Eric AF
Published: (2002-06-01)

Comparing of two different epidemic seasons of bronchiolitis
by: Simonetta Picone, et al.
Published: (2018-01-01)

Re-comparing of three different epidemic seasons of bronchiolitis: different prophylaxis approaches
by: Simonetta Picone, et al.
Published: (2018-12-01)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
by: Renato Cutrera, et al.
Published: (2019-11-01)

Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper
by: Susanna Esposito, et al.
Published: (2021-08-01)

Bronchiolitis - diagnostic and therapeutic difficulties in pediatric patients
by: Iwona Kowalska, et al.
Published: (2020-03-01)

Patient equity and respiratory syncytial virus Immunoprophylaxis
by: H. Cody Meissner
Published: (2019-01-01)

Survival of recombinant monoclonal and naturally-occurring human milk immunoglobulins A and G specific to respiratory syncytial virus F protein across simulated human infant gastrointestinal digestion
by: Jiraporn Lueangsakulthai, et al.
Published: (2020-10-01)

Immunoprophylaxis of Respiratory Syncytial Virus Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study
by: Ruomei Xu, et al.
Published: (2020-10-01)

Bronchiolitis in children: The Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO)
by: Adel S Alharbi, et al.
Published: (2018-01-01)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
by: Alessandro Rocca, et al.
Published: (2021-04-01)

A CLINICAL AND ECONOMICAL ANALYSIS OF THE RESULTS PRODUCED BY THE PROGRAM OF RSV-INFECTION PROPHYLAXIS DURING THE EPIDEMIOLOGICAL SEASON OF 2012/2013 IN MOSCOW
by: V. I. Ignat'eva, et al.
Published: (2013-11-01)

Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model
by: Jiraporn Lueangsakulthai, et al.
Published: (2020-02-01)